|Bid||1.65 x 5800|
|Ask||1.75 x 100|
|Day's range||1.83 - 1.99|
|52-week range||0.63 - 4.25|
|PE ratio (TTM)||N/A|
|Earnings date||13 Mar 2018 - 19 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.60|
Capricor Therapeutics (NASDAQ:CAPR) announced today that it has added seven new patent applications to its existing Exclusive License Agreements with Cedars-Sinai Medical Center for technologies related to cardiosphere-derived cells (CDCs) and CDC-derived extracellular vesicles, including exosomes. The Exclusive License Agreements with Cedars-Sinai grant Capricor exclusive worldwide rights to commercially develop and market CDCs, which comprise Capricor’s lead investigational cell therapy, CAP-1002, as well as CDC-derived exosomes, which comprise its lead investigational exosome-based therapy candidate, CAP-2003. The new patent applications expand the scope of the Exclusive License Agreements to enable Capricor to develop new therapeutic indications for its cellular and exosome therapies in Duchenne muscular dystrophy, ventricular tachyarrhythmia, cancer and age-related disorders.
Capricor Therapeutics Inc. shares rose nearly 18% in extremely heavy Wednesday morning trade after the company said the Food and Drug Administration has cleared its Duchenne muscular dystrophy therapy ...
The Beverly Hills, California-based company said it had a loss of 12 cents per share. The biotechnology company posted revenue of $313,300 in the period. Its adjusted revenue was $313,000. In the final ...
Capricor Therapeutics (CAPR) was a big mover last session, as the company saw its shares rise almost 14% on the day amid huge volumes.